Department of Public Health and Human Services

Montana Healthcare Programs Provider Information » Drug Use Review (DUR) Board

Main Content

Drug Use Review (DUR) Board

Drug Use Review (DUR) Board
Formulary Committee

DUR Board Meeting Agendas

2017 Agendas

December 6, 2017

September 27, 2017

April 26, 2017 - PDL Revised 04/07/2017

- DOI Link, Feldman Int J Chron Obstruct Pulmon Dis

- Epclusa® Clinical Review Summary

- Taltz® Medical Value Summary

- EucrisaTM AMCP Dossier

- Med Info Letter Xeljanz® XR

- Montana Medicaid Final Chantix®

March 29, 2017 - PDL Revised 03/14/2017

Rexulti®

- Restasis®

- Aristada®

February 15, 2017 - PDL

- Chest Guidelines for VTE Servlet

- Entresto®

- Ocaliva® Letter

- Ocaliva® AMCP Dossier

- Summary Eliquis® Servlet

January 25, 2017 - DURB

2016 Agendas

September 28, 2016

August 31, 2016 Revised 08.18.2016

April 27, 2016 Revised 04.21.2016

- Dyanavel XR® Formulary Submission

- Pfizer Medical Information for QuilliChew ER C-II

- A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of SchizophreniaJ Clin Psychiatry Meltzer et al. 2015

March 30, 2016 Revised 03.09.2016

- Cosentyx ® (secukinumab) Clinic Summary

- Humira® (Adalimumab) Medicaid Testimony

- Seebri® Neohaler® (glycopyrrolate) inhalation powder Clinical Summary

- Technivie® (ombitasvir, paritaprevir, and ritonavir tablets) Medicaid Testimony

- Tudorza ® Pressair® (Aclidinium bromide inhalation powder) Clinical Executive Summary

- Utibron ® Neohaler® (indacaterol and glycopyrrolate) inhalation powder Clinical Summary

February 17, 2016

- Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension for AMBITION investigators  N Engl J Med 373;9 nejm.org August 27, 2015

Supplementary Appendix to Initial Use of Ambrisentan Plus Tadalafil in Pulmonary Arterial Hypertension 

N Engl J Med 2015;373:834-44. DOI: 10.1056/NEJMoa1413687

- Entresto® (sacubitril and valsartan) Clinical Summary for Formulary Review

- Montana Medicaid Repatha (Evolucumab) Submission

- Movantik

January 20, 2016

2015 Agendas

October 28, 2015

September 30, 2015 Rev. 09.16.2015

April 29, 2015

- Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity:results from a randomized controlled trial in relapsing-remitting multiple sclerosis Arnold et al. BMC Neurology

- Bunavail® (Buprenorphine/naloxone)

- Hysingla® Formulary Dossier

- Lemtrada™

- Abilify® (aripiprazole) Testimony – Montana Medicaid

- Plegridy™ Summary Medicaid Pharmacy &Therapeutics Committee

- Suboxone® Sublingual Film

- Novel Buccal Film Formulation of Bupenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence:A 12-Week Conversion Study Sullivan and Webster, Clinical Therapeutics/2015

- Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures Fountain, et al.  Epilepsia, 54(1):58–65, 2013

March 25, 2015 Revised 03.04.2015

- Arnuity Product Summary

- Incruse Ellipta Prescribing Information

- Incruse Ellipta Product Summary

- Otezla Medicaid Summary

- Ruconest Dossier

February 18, 2015 Revised 02.10.2015

- Akynzeo® Formulary Dossier

- Trulicity™ Medical Value Summary, November 3, 2014

- Tanzeum™ Product Summary

- Viekira Pak® Medicaid Clinical Summary, December 2014

- Xigduo™ XR Clinical Summary, November 2014

January 28, 2015

 

DUR Board Meeting Minutes

To locate older documents, access the Archive Page.